Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.

ABSTRACT: Genetic engineering of tumor cells to express immune-stimulatory molecules, including cytokines and co-stimulatory ligands, is a promising approach to generate highly efficient cancer vaccines. The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity. However, because LIGHT binds two additional receptors, lymphotoxin β receptor and Decoy receptor 3, there are significant concerns that tumor-associated LIGHT results in both unexpected adverse events and interference with the ability of the vaccine to enhance antitumor immunity. In order to overcome these problems, we generated tumor cells expressin

SUBMITTER: Park JJ 

PROVIDER: S-EPMC3746333 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature